Months earlier, the agency released a report alleging the companies drove up the costs of some medications, including insulin.

The FTC is suing three pharmacy benefit managers for allegedly driving up the cost of insulin, but there is very little other federal action targeting PBMs, which is why 22 states in 2024 have done just that.

The Federal Trade Commission on Friday filed a lawsuit over insulin prices against the three largest pharmaceutical middlemen that negotiate prescription drug prices, arguing that the companies artificially inflate the costs of the lifesaving diabetes drug for patients.